Pakeeran Siriratnam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pakeeran Siriratnam has a total of 233 co-authors. Here are the top co-authors by number of shared publications:
- Saif Huda
Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, United Kingdom
7 shared publications - Anneke van der Walt
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia
5 shared publications Katherine Buzzard
Department of Neurology, Eastern Health, Melbourne, Australia
4 shared publications- Mastura Monif
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia
4 shared publications - Tomas Kalincik
Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
4 shared publications - Vilija G. Jokubaitis
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia
4 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (6) , e200651
Clinical Prognostic Factors Associated With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
Background and ObjectivesIt is currently difficult to accurately predict who, after the index event of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), will develop relapsin...
- 1 November 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (6) , e200651
Open AccessClinical Prognostic Factors Associated With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
Background and ObjectivesIt is currently difficult to accurately predict who, after the index event of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), will develop relapsin...
- 29 October 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (11) , 692
Longitudinal inflammatory and neurodegenerative outcomes in cerebral amyloid angiopathy-related inflammation: a case series
- 29 October 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (11) , 692
Longitudinal inflammatory and neurodegenerative outcomes in cerebral amyloid angiopathy-related inflammation: a case series
- 10 July 2026
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (10) , 918-922
Inter-attack serum GFAP and NfL remain stable over 9 years in AQP4 IgG NMOSD
Background and objectives: Disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum disease (AQP4-IgG NMOSD) is considered relapse-driven although subclinical injury has been suggested by neuroimaging and visual pathway assessments. We investigated longitudinal changes in serum glial fibrillar acidic protein (sGFAP) and neurofilament light chain (sNfL) during relapse-free periods. Methods: We conducted a retrospective longitudinal study (2008–2025) at a UK national referral centre for NMOSD. Patients with ≥3 serum samples collected over ≥3 years were included; samples within 3 months of relapses were excluded. Longitudinal changes in sGFAP and sNfL were assessed using linear mixed-effects models with random intercepts and generalised estimating equations, adjusting for age, sex and time. Results: 40 patients (87.5% females; 162 samples; median onset age 40.1 years) and 28 matched controls were included. Over the course of four measurements and a median sampling over 9 years, stability was observed in sGFAP levels (99.2 pg/mL at 0–2.5 years (95% CI 84.2 to 117.0) to 90.3 pg/mL at 7.5–10 years (95% CI 74.7 to 109.0), p=0.65) and sNfL levels (12.0 pg/mL at 0–2.5 years (95% CI 10.8 to 13.3) to 10.4 pg/mL (9.1 to 11.8) at 7.5–10 years, p=0.12) after adjustment for covariates. Discussion: In this longitudinal study, mean sGFAP and sNfL levels remained stable over 9 years of sequential measurements during relapse-free periods, supporting the relapse-driven nature of NMOSD pathology.
- 10 July 2026
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (10) , 918-922
Inter-attack serum GFAP and NfL remain stable over 9 years in AQP4 IgG NMOSD
Background and objectives: Disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum disease (AQP4-IgG NMOSD) is considered relapse-driven although subclinical injury has been suggested by neuroimaging and visual pathway assessments. We investigated longitudinal changes in serum glial fibrillar acidic protein (sGFAP) and neurofilament light chain (sNfL) during relapse-free periods. Methods: We conducted a retrospective longitudinal study (2008–2025) at a UK national referral centre for NMOSD. Patients with ≥3 serum samples collected over ≥3 years were included; samples within 3 months of relapses were excluded. Longitudinal changes in sGFAP and sNfL were assessed using linear mixed-effects models with random intercepts and generalised estimating equations, adjusting for age, sex and time. Results: 40 patients (87.5% females; 162 samples; median onset age 40.1 years) and 28 matched controls were included. Over the course of four measurements and a median sampling over 9 years, stability was observed in sGFAP levels (99.2 pg/mL at 0–2.5 years (95% CI 84.2 to 117.0) to 90.3 pg/mL at 7.5–10 years (95% CI 74.7 to 109.0), p=0.65) and sNfL levels (12.0 pg/mL at 0–2.5 years (95% CI 10.8 to 13.3) to 10.4 pg/mL (9.1 to 11.8) at 7.5–10 years, p=0.12) after adjustment for covariates. Discussion: In this longitudinal study, mean sGFAP and sNfL levels remained stable over 9 years of sequential measurements during relapse-free periods, supporting the relapse-driven nature of NMOSD pathology.
- 14 April 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (7) , e214707
Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder
Previous studies have reported inconsistent findings regarding the impact of age at onset on relapse risk in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), although older disease onset has been linked to more rapid disability accrual. This is in contrast to multiple sclerosis, where advancing age and older onset are associated with reduced relapse activity, allowing for treatment de-escalation or discontinuation in some older patients. The aim of this study was to clarify the influence of age at onset on relapse risk as well as disability accrual in a large, international cohort of patients with NMOSD. We conducted a retrospective, multicenter cohort study using the MSBase data registry to evaluate annualized relapse rates (ARRs), time to first relapse, and time to Expanded Disability Status Scale (EDSS) scores of 4 and 6. For inclusion, a diagnosis of AQP4-IgG NMOSD according to the latest iteration of the criteria and availability of the minimum data set were required. Patients were stratified as pediatric onset (55 years of age). Analyses included patients on high-efficacy therapy (HET), those on low-efficacy therapy (LET), and an incident cohort with the first clinical visit within 12 months from disease onset. Predictors of first relapse and EDSS 4/6 thresholds were analyzed using Cox proportional models. Data from 539 patients (42 pediatric, 421 with early onset, 76 with late onset; 85.2% female) with a median age at onset of 35 years (Q1 25.10, Q3 47.60) and a disease duration of 7.42 years (Q1 3.23, Q3 13.10) were analyzed. ARR and time to first relapse were not influenced by age at disease onset. Patients on HET had fewer relapses than those on LET (p < 0.001). Older age was linked to faster disability accumulation. In addition, higher baseline EDSS scores and delayed treatment were independent predictors of future disability. Our study demonstrates that while age at onset does not affect relapse risk, older patients experience more rapid disability accrual. These findings underscore the importance of early initiation of effective preventive immunotherapy in all age groups. The primary limitations of this study pertain to its retrospective design and the sole reliance on EDSS for disability assessment.
- 14 April 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (7) , e214707
Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder
Previous studies have reported inconsistent findings regarding the impact of age at onset on relapse risk in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), although older disease onset has been linked to more rapid disability accrual. This is in contrast to multiple sclerosis, where advancing age and older onset are associated with reduced relapse activity, allowing for treatment de-escalation or discontinuation in some older patients. The aim of this study was to clarify the influence of age at onset on relapse risk as well as disability accrual in a large, international cohort of patients with NMOSD. We conducted a retrospective, multicenter cohort study using the MSBase data registry to evaluate annualized relapse rates (ARRs), time to first relapse, and time to Expanded Disability Status Scale (EDSS) scores of 4 and 6. For inclusion, a diagnosis of AQP4-IgG NMOSD according to the latest iteration of the criteria and availability of the minimum data set were required. Patients were stratified as pediatric onset (55 years of age). Analyses included patients on high-efficacy therapy (HET), those on low-efficacy therapy (LET), and an incident cohort with the first clinical visit within 12 months from disease onset. Predictors of first relapse and EDSS 4/6 thresholds were analyzed using Cox proportional models. Data from 539 patients (42 pediatric, 421 with early onset, 76 with late onset; 85.2% female) with a median age at onset of 35 years (Q1 25.10, Q3 47.60) and a disease duration of 7.42 years (Q1 3.23, Q3 13.10) were analyzed. ARR and time to first relapse were not influenced by age at disease onset. Patients on HET had fewer relapses than those on LET (p < 0.001). Older age was linked to faster disability accumulation. In addition, higher baseline EDSS scores and delayed treatment were independent predictors of future disability. Our study demonstrates that while age at onset does not affect relapse risk, older patients experience more rapid disability accrual. These findings underscore the importance of early initiation of effective preventive immunotherapy in all age groups. The primary limitations of this study pertain to its retrospective design and the sole reliance on EDSS for disability assessment.
- 24 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (4) , e214613
Timing for Starting Antiseizure Medication Withdrawal After Epilepsy Surgery in Adults
More than half of people undergoing epilepsy surgery become seizure-free and may consider withdrawing antiseizure medications (ASMs). Withdrawal practices vary, and the optimal timing remains unclear. We aim to compare seizure relapse risk among individuals initiating ASM withdrawal at different time points after epilepsy surgery. We conducted a multicenter observational cohort study of adults who underwent resective epilepsy surgery between 1990 and 2016 at 12 tertiary centers. Participants were seizure-free before medication withdrawal and had at least 1 year of follow-up. Seizure relapse risk was compared among those initiating withdrawal 1, 2, 3, 4, or 5 years postoperatively vs later. We used propensity score matching for each comparison to adjust for treatment selection bias. Of the 964 people included (51% female; median age at surgery 34 years [interquartile range 26-44]), 446 (46%) began ASM withdrawal in the first year after surgery, 255 (26%) in the second, 110 (11%) in the third, 58 (6%) in the fourth, 29 (3%) in the fifth, and 66 (7%) after the fifth year. After matching, those starting withdrawal in the first (hazard ratio [HR] 1.4; p = 0.003) or second (HR 1.18; p < 0.001) year had a higher risk of relapse than those who withdrew later. Starting withdrawal in the third (HR 1.7; p = 0.12), fourth (HR 1.3; p = 0.45), or fifth (HR 0.17; p = 0.82) year after surgery showed no increase in risk compared with later withdrawal. Long-term outcomes, such as seizure freedom and being entirely off ASMs at the final follow-up, were not substantially associated with withdrawal timing. Initiating ASM withdrawal within the first 2 postoperative years was linked to a higher initial risk of seizure relapse compared with later withdrawal, although long-term outcomes were similar regardless of withdrawal timing. Waiting more than 2 years did not confer additional benefit in reducing seizure risk. Deciding whether and when to withdraw ASMs is a shared process involving individuals, caregivers, and clinicians, balancing preferences, risk of injury, social factors (e.g., driving, work, and supervision), and clinical judgment. Transparent information on risks and benefits is essential. Our findings offer real-world evidence that may inform future evidence-based withdrawal protocols and follow-up strategies.
- 24 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (4) , e214613
Timing for Starting Antiseizure Medication Withdrawal After Epilepsy Surgery in Adults
More than half of people undergoing epilepsy surgery become seizure-free and may consider withdrawing antiseizure medications (ASMs). Withdrawal practices vary, and the optimal timing remains unclear. We aim to compare seizure relapse risk among individuals initiating ASM withdrawal at different time points after epilepsy surgery. We conducted a multicenter observational cohort study of adults who underwent resective epilepsy surgery between 1990 and 2016 at 12 tertiary centers. Participants were seizure-free before medication withdrawal and had at least 1 year of follow-up. Seizure relapse risk was compared among those initiating withdrawal 1, 2, 3, 4, or 5 years postoperatively vs later. We used propensity score matching for each comparison to adjust for treatment selection bias. Of the 964 people included (51% female; median age at surgery 34 years [interquartile range 26-44]), 446 (46%) began ASM withdrawal in the first year after surgery, 255 (26%) in the second, 110 (11%) in the third, 58 (6%) in the fourth, 29 (3%) in the fifth, and 66 (7%) after the fifth year. After matching, those starting withdrawal in the first (hazard ratio [HR] 1.4; p = 0.003) or second (HR 1.18; p < 0.001) year had a higher risk of relapse than those who withdrew later. Starting withdrawal in the third (HR 1.7; p = 0.12), fourth (HR 1.3; p = 0.45), or fifth (HR 0.17; p = 0.82) year after surgery showed no increase in risk compared with later withdrawal. Long-term outcomes, such as seizure freedom and being entirely off ASMs at the final follow-up, were not substantially associated with withdrawal timing. Initiating ASM withdrawal within the first 2 postoperative years was linked to a higher initial risk of seizure relapse compared with later withdrawal, although long-term outcomes were similar regardless of withdrawal timing. Waiting more than 2 years did not confer additional benefit in reducing seizure risk. Deciding whether and when to withdraw ASMs is a shared process involving individuals, caregivers, and clinicians, balancing preferences, risk of injury, social factors (e.g., driving, work, and supervision), and clinical judgment. Transparent information on risks and benefits is essential. Our findings offer real-world evidence that may inform future evidence-based withdrawal protocols and follow-up strategies.
- 25 August 2025
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 31 (11) , 1278-1280
Patients with rheumatological diseases should routinely be tested for aquaporin-4 (AQP4) antibodies: No
- 25 August 2025
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 31 (11) , 1278-1280
Patients with rheumatological diseases should routinely be tested for aquaporin-4 (AQP4) antibodies: No
- Open Access
- 18 April 2025
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 31 (13) , 1604-1607
A first report of progressive multifocal leukoencephalopathy in childhood-onset NMOSD
Background: Progressive multifocal leukoencephalopathy (PML) has not been reported in pediatric neuromyelitis optica spectrum disorder (NMOSD) and rarely described in children. Objectives: To report a case of PML in childhood-onset NMOSD. Methods: A single retrospective case report. Results: Nine years after diagnosis of aquaporin-4 antibody positive NMOSD, a 17-year-old boy treated with rituximab presented with painless right visual loss over 6 weeks coinciding with CD19 repopulation. Acute relapse treatment was given but he continued to deteriorate, and JC virus was detected in cerebrospinal fluid confirming PML. Conclusion: PML can occur in childhood-onset NMOSD and protracted clinical presentations with unusual radiological features should prompt JCV testing. Balancing effective immunosuppression while mitigating the risks of associated complications in long-term relapsing conditions remains a challenge.
- 18 April 2025
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 31 (13) , 1604-1607
Open AccessA first report of progressive multifocal leukoencephalopathy in childhood-onset NMOSD
Background: Progressive multifocal leukoencephalopathy (PML) has not been reported in pediatric neuromyelitis optica spectrum disorder (NMOSD) and rarely described in children. Objectives: To report a case of PML in childhood-onset NMOSD. Methods: A single retrospective case report. Results: Nine years after diagnosis of aquaporin-4 antibody positive NMOSD, a 17-year-old boy treated with rituximab presented with painless right visual loss over 6 weeks coinciding with CD19 repopulation. Acute relapse treatment was given but he continued to deteriorate, and JC virus was detected in cerebrospinal fluid confirming PML. Conclusion: PML can occur in childhood-onset NMOSD and protracted clinical presentations with unusual radiological features should prompt JCV testing. Balancing effective immunosuppression while mitigating the risks of associated complications in long-term relapsing conditions remains a challenge.
- 28 December 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (2) , 539-548
The impacts of the COVID-19 pandemic on Australia’s myasthenia gravis patients: A self-reported survey study
Introduction/Aims Previous studies have demonstrated high morbidity and mortality in patients with myasthenia gravis (MG) who acquired COVID-19. We aimed to identify the impact of the pandemic on MG disease control, treatment and quality of life. Methods A prospective observational cohort study was conducted to identify the impact of the COVID-19 pandemic on Australian patients with MG. We conducted an online survey through Myasthenia Alliance Australia from May 2022 to July 2022. Results Among the 229 patients who responded to the survey, most patients had three (80; 34.9%) or four (116; 50.7%) doses of the COVID-19 vaccines, 65 (28.4%) had contracted COVID-19, with 6 patients (9.4%) requiring hospitalisation. A large proportion of patients responded that the pandemic had no impact on their MG disease control (123; 53.7%) or treatment (111; 48.5%). Most patients felt the pandemic had either a mild (111; 48.5%) or moderate (50; 21.8%) impact on their mood. Conclusion Our study provides a snapshot of the types of impacts experienced by myasthenic patients during the pandemic, in particular the psychosocial effects. As we continue to live with COVID-19, clinicians should consider its various impacts in the holistic management of their patients.
- 28 December 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (2) , 539-548
The impacts of the COVID-19 pandemic on Australia’s myasthenia gravis patients: A self-reported survey study
Introduction/Aims Previous studies have demonstrated high morbidity and mortality in patients with myasthenia gravis (MG) who acquired COVID-19. We aimed to identify the impact of the pandemic on MG disease control, treatment and quality of life. Methods A prospective observational cohort study was conducted to identify the impact of the COVID-19 pandemic on Australian patients with MG. We conducted an online survey through Myasthenia Alliance Australia from May 2022 to July 2022. Results Among the 229 patients who responded to the survey, most patients had three (80; 34.9%) or four (116; 50.7%) doses of the COVID-19 vaccines, 65 (28.4%) had contracted COVID-19, with 6 patients (9.4%) requiring hospitalisation. A large proportion of patients responded that the pandemic had no impact on their MG disease control (123; 53.7%) or treatment (111; 48.5%). Most patients felt the pandemic had either a mild (111; 48.5%) or moderate (50; 21.8%) impact on their mood. Conclusion Our study provides a snapshot of the types of impacts experienced by myasthenic patients during the pandemic, in particular the psychosocial effects. As we continue to live with COVID-19, clinicians should consider its various impacts in the holistic management of their patients.
- 24 December 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (12) , e209940
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG–Positive NMOSD
In aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), disability accrual is mostly attributed to relapses. This study aimed to assess the prevalence of progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) in AQP4-IgG NMOSD. This was a retrospective cohort study of patients with AQP4-IgG NMOSD enrolled in the MSBase international data registry. Patients required a minimum of 3 recorded Expanded Disability Status Scale (EDSS) scores: baseline, event, and a 6-month confirmation score. Presence and absence of relapses between the baseline and event EDSS scores determined RAW and PIRA, respectively. Descriptive statistics were used to present the results. A total of 181 patients followed for a median of 4.5 years (Q1 1.7, Q3 7.8) were included. Most patients were female (88.4%), and the median age at disease onset was 38.1 years. Overall, 4 patients (2.2%) developed 5 incidences of PIRA and 13 patients developed RAW (7.2%). This multicenter study highlights that PIRA is very rare in AQP4-IgG NMOSD. Limitations of this study include the sole focus of overall EDSS to measure disability, lack of requirement for a second EDSS score to confirm baseline EDSS, and the absence of magnetic resonance imaging information for all patients.
- 24 December 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (12) , e209940
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG–Positive NMOSD
In aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), disability accrual is mostly attributed to relapses. This study aimed to assess the prevalence of progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) in AQP4-IgG NMOSD. This was a retrospective cohort study of patients with AQP4-IgG NMOSD enrolled in the MSBase international data registry. Patients required a minimum of 3 recorded Expanded Disability Status Scale (EDSS) scores: baseline, event, and a 6-month confirmation score. Presence and absence of relapses between the baseline and event EDSS scores determined RAW and PIRA, respectively. Descriptive statistics were used to present the results. A total of 181 patients followed for a median of 4.5 years (Q1 1.7, Q3 7.8) were included. Most patients were female (88.4%), and the median age at disease onset was 38.1 years. Overall, 4 patients (2.2%) developed 5 incidences of PIRA and 13 patients developed RAW (7.2%). This multicenter study highlights that PIRA is very rare in AQP4-IgG NMOSD. Limitations of this study include the sole focus of overall EDSS to measure disability, lack of requirement for a second EDSS score to confirm baseline EDSS, and the absence of magnetic resonance imaging information for all patients.
- 4 September 2024
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (4) , 361-369
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
Background Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD. Methods This was a multicentre, international, retrospective cohort study using the MSBase registry. Recurrent relapse risk was assessed using an Andersen-Gill model and risk of first relapse was evaluated using a Cox proportional hazards model. Covariates that putatively influence relapse risk included demographic factors, clinical characteristics and immunosuppressive therapies; the latter was assessed as a time-varying covariate. Results A total of 398 patients (246 AQP4-IgG NMOSD and 152 seronegative NMOSD) were included. The AQP4-IgG NMOSD and seronegative NMOSD patients did not significantly differ by age at disease onset, ethnicity or annualised relapse rate. Both low-efficacy and high-efficacy immunosuppressive therapies were associated with significant reductions in recurrent relapse risk, with notably greater protection conferred by high-efficacy therapies in both AQP4-IgG NMOSD (HR 0.27, 95% CI 0.15 to 0.49, pConclusion Although further studies are needed to improve our understanding of seronegative NMOSD, our findings underscore the importance of aggressive treatment with high-efficacy immunotherapies in both NMOSD subtypes, regardless of serostatus.
- 4 September 2024
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (4) , 361-369
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
Background Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD. Methods This was a multicentre, international, retrospective cohort study using the MSBase registry. Recurrent relapse risk was assessed using an Andersen-Gill model and risk of first relapse was evaluated using a Cox proportional hazards model. Covariates that putatively influence relapse risk included demographic factors, clinical characteristics and immunosuppressive therapies; the latter was assessed as a time-varying covariate. Results A total of 398 patients (246 AQP4-IgG NMOSD and 152 seronegative NMOSD) were included. The AQP4-IgG NMOSD and seronegative NMOSD patients did not significantly differ by age at disease onset, ethnicity or annualised relapse rate. Both low-efficacy and high-efficacy immunosuppressive therapies were associated with significant reductions in recurrent relapse risk, with notably greater protection conferred by high-efficacy therapies in both AQP4-IgG NMOSD (HR 0.27, 95% CI 0.15 to 0.49, pConclusion Although further studies are needed to improve our understanding of seronegative NMOSD, our findings underscore the importance of aggressive treatment with high-efficacy immunotherapies in both NMOSD subtypes, regardless of serostatus.